{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Extraction+Phase&page=11", "query": { "intervention": "Extraction Phase", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 374, "total_pages": 38, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Extraction+Phase&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Extraction+Phase&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T11:46:31.728Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05672459", "title": "A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Single Injection of IVS-3001- Anti - HLA-G CAR-T cells", "type": "DRUG" }, { "name": "Fludarabine phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2023-06-21", "completion_date": "2028-12-29", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-28T11:46:31.728Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05672459" }, { "nct_id": "NCT03710421", "title": "CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "CS1-CAR T Therapy", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-04-23", "completion_date": "2027-02-23", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-28T11:46:31.728Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03710421" }, { "nct_id": "NCT04025879", "title": "A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 461, "start_date": "2019-11-05", "completion_date": "2027-07-31", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-28T11:46:31.728Z", "location_count": 15, "location_summary": "Tampa, Florida • Atlanta, Georgia • Augusta, Georgia + 11 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04025879" }, { "nct_id": "NCT01983761", "title": "Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Blood And Marrow Transplantation", "Leukemia", "Lymphoma", "Transplantation Infection", "Myelodysplastic Syndrome (MDS)", "Non-Hodgkin's Lymphoma (NHL)", "Hodgkin's Lymphoma" ], "interventions": [ { "name": "Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)", "type": "DRUG" }, { "name": "Fludarabine, Melphalan, ATG (Reduced Intensity)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Targazyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "80 Years", "sex": "ALL", "summary": "1 Year to 80 Years" }, "enrollment_count": 25, "start_date": "2013-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-11-18", "last_synced_at": "2026-10-28T11:46:31.728Z", "location_count": 4, "location_summary": "La Jolla, California • Cleveland, Ohio • Houston, Texas + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01983761" }, { "nct_id": "NCT00715442", "title": "Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Sunitinib", "type": "DRUG" }, { "name": "Nephrectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 50, "start_date": "2008-06-24", "completion_date": "2026-12-04", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-28T11:46:31.728Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00715442" }, { "nct_id": "NCT04881240", "title": "Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia, in Relapse", "Acute Lymphoblastic Leukemia, Refractory", "Pediatric ALL" ], "interventions": [ { "name": "CD19-CAR(Mem) T-cells", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "CliniMACS", "type": "DEVICE" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 60, "start_date": "2024-02-14", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-28T11:46:31.728Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04881240" }, { "nct_id": "NCT04209114", "title": "A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer", "Bladder Tumor", "Muscle-Invasive Bladder Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Radical cystectomy (RC)", "type": "PROCEDURE" }, { "name": "Bempegaldesleukin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2020-02-05", "completion_date": "2023-06-07", "has_results": true, "last_update_posted_date": "2024-06-27", "last_synced_at": "2026-10-28T11:46:31.728Z", "location_count": 15, "location_summary": "Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 12 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04209114" }, { "nct_id": "NCT04670575", "title": "Vivity Outcomes in Patients With Early Stage Glaucoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Glaucoma", "Cataract", "Presbyopia" ], "interventions": [ { "name": "Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Vance Thompson Vision", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 27, "start_date": "2021-01-01", "completion_date": "2022-11-30", "has_results": false, "last_update_posted_date": "2024-05-20", "last_synced_at": "2026-10-28T11:46:31.728Z", "location_count": 1, "location_summary": "Sioux Falls, South Dakota", "locations": [ { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04670575" }, { "nct_id": "NCT02618031", "title": "The Capillary Index Score Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Stroke", "Brain Ischemia", "Ischemic Stroke" ], "interventions": [ { "name": "Endovascular Treatment (EVT)", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Firas Al-Ali", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2016-03-01", "completion_date": "2018-12-31", "has_results": true, "last_update_posted_date": "2020-02-05", "last_synced_at": "2026-10-28T11:46:31.728Z", "location_count": 6, "location_summary": "Atlanta, Georgia • New York, New York • Rochester, New York + 3 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Akron", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02618031" }, { "nct_id": "NCT00003229", "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "tyrosinase peptide", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": null, "start_date": "1997-07", "completion_date": "2005-02", "has_results": false, "last_update_posted_date": "2013-03-25", "last_synced_at": "2026-10-28T11:46:31.728Z", "location_count": 2, "location_summary": "Durham, North Carolina • Charlottesville, Virginia", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003229" } ] }